Neurocrine Biosciences to Present at Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Neurocrine Biosciences (Nasdaq: NBIX) said members of its management team will present at two investor conferences: a Jefferies Global Healthcare Conference fireside chat on November 18, 2025 at 12:00 PM GMT (7:00 AM ET) in London, and a Piper Sandler 37th Annual Healthcare Conference fireside chat on December 2, 2025 at 9:30 AM ET in New York.
Both presentations will be live webcast via the company's Investors page at www.neurocrine.com. Replays will be posted about one hour after each event and will be archived for approximately one month.
Details
News Market Reaction – NBIX
On Nov 12, the first trading day after this news, NBIX closed 0.30% below the previous close.
Data tracked by StockTitan Argus for the Nov 12 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
-
Jefferies Global Healthcare Conference. Fireside chat on Tuesday, November 18, 2025 at 12:00 PM GMT (7:00 AM ET) in
London -
Piper Sandler 37th Annual Healthcare Conference. Fireside chat on Tuesday, December 2, 2025 at 9:30 AM ET in
New York, NY
The live webcasts can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-302611943.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.